NASDAQ · ONCS
Healthcare · Biotechnology
$0.28
Up+$0.07 (+31.87%)
Updated Sep 10, 2026, 4:28 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
ONCS does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning ONCS.
ONCS research
Company profile and research snapshot.
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor. It is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in clinical trials collaboration and supply agreement (KEYNOTE-695) and metastatic triple negative breast cancer, which is in Phase II clinical trials (KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, the company is developing monotherapy biomarker study in patients with advanced or metastatic TNBC that has completed the Phase II clinical trials; and technology to treat liver, lung, bladder, pancreatic, and other visceral lesions. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890 studies; a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine; a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park's intravital microscopy and enhanced IL-12 DNA-plasmid; and collaboration with Providence Cancer Institute. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. The company was incorporated in 2008 and is headquartered in Pennington, New Jersey.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 14, 2022 | BTIG | Neutral | — |
| Mar 16, 2022 | BTIG | Buy | — |
| Mar 8, 2021 | BTIG | Buy | — |
| Jul 27, 2020 | Dawson James | Buy | — |
| Nov 7, 2018 | H.C. Wainwright | Neutral | — |
No generated briefing is available yet.
PennyStocks · May 16, 2023
Hot penny stocks with big news this week. The post 3 Top Penny Stocks To Watch After Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
PennyStocks · Mar 3, 2023
Use these tips for avoiding common penny stocks The post Avoid Common Penny Stocks Trading Mistakes With These Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Benzinga · Mar 2, 2023
Investors are on the hunt for undervalued, underfollowed and emerging stocks to spot opportunities. Retail traders have countless methods at their disposal to uncover new information. For some, this may be overwhelming. Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks each week that are just under the surface and warrant attention. The index layers editorial commentary to help make sense of why these stocks are of interest and whether they broach an area for investors and casual readers to watch. Here is a look at the Benzinga Stock Whisper Index for the week of March 2, 2023. China Jo-Jo Drugstores Holdings Inc (NASDAQ: CJJD): China Jo-Jo is a leading online and offline pharmaceutical retailer and distributor in China. The company places high on the Stock Whisper Index with increased chatter among Benzinga’s proprietary data. China Jo-Jo was recently highlighted by Benzinga as a potential short squeeze using data from Fintel. The stock ranked third on the weekly short squeeze leaderboard with 10.7% of the float short and a cost to borrow ...
Benzinga · Mar 2, 2023
U.S. stocks traded mixed this morning, with the Dow Jones gaining around 80 points on Thursday. Following the market opening Thursday, the Dow traded up 0.24% to 32,740.88 while the NASDAQ fell 0.58% to 11,313.95. The S&P 500 also fell, dropping, 0.30% to 3,939.53. Check This Out: Top 5 Materials Stocks That Could Lead To Your Biggest Gains In March Leading and Lagging Sectors Consumer staples shares rose 0.4% on Thursday. Meanwhile, top gainers in the sector included Utz Brands, Inc. (NYSE: UTZ), up 10%, and Sprouts Farmers Market, Inc. (NASDAQ: SFM), up 12%. In trading on Thursday, financial shares fell by 1.4%. Top Headline US jobless claims fell by 2,000 from the prior week to 190,000 for the week ending Feb. 25, compared to market estimates of 195,000. Equities Trading UP BioRestorative Therapies, Inc. (NASDAQ: BRTX) shares shot up 32% to $3.6900 after the company announced the United States Patent and Trademark Office has issued a notice of allowance for a patent application related to the Company's metabolic ThermoStem program. Shares of OncoSec Medical Incorporated (NASDAQ: ONCS) got a boost, shooting 29% to $2.6350. OncoSec Medical ...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ONCS.
No results
No recent SID articles mention ONCS.
